SBI Securities’s enGene Therapeutics ENGN Stock Holding History

SBI Securities’s Portfolio ENGN Stock Details ENGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$56	Hold	28	–	–	﹤0.01%	3709
2026 Q2	$48	Hold	28	–	–	﹤0.01%	3680
2026 Q1	$191	Hold	28	–	–	﹤0.01%	3235
2025 Q4	$253	Sell	28 -3	-10%	-$24	﹤0.01%	3137
2025 Q3	$212	Buy	31 +1	+3%	+$5	﹤0.01%	3298
2025 Q2	$109	Hold	30	–	–	﹤0.01%	3512
2025 Q1	$134	Hold	30	–	–	﹤0.01%	3348
2024 Q4	$200	Buy	+30	New	+$233	﹤0.01%	3240

Other funds holding ENGN

Peapod Lane Capital Bedford Hills, New York $134M AUM 63.91% 1-Year Est. Return

PFS Partners Mine Hill, New Jersey $246M AUM 22.61% 1-Year Est. Return

Indivisible Partners Clearwater, Florida $2.18B AUM 33.61% 1-Year Est. Return

Covestor London, United Kingdom $157M AUM 35.87% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

SBI Securities's ENGN Position: Q3 2026 in Review

SBI Securities held its enGene Therapeutics (ENGN) position steady in Q3 2026 at 28 shares worth $56. The position accounts for ﹤0.01% of the portfolio, ranked #3709.

SBI Securities first reported a position in ENGN in Q4 2024 and has held it in 8 quarters since. The position peaked at $253 in Q4 2025. 6 funds tracked by Wall St. Rank hold ENGN as of Q3 2026.

SBI Securities held 28 shares of enGene Therapeutics worth $56 as of Q3 2026.
SBI Securities left its enGene Therapeutics share count unchanged in Q3 2026.
enGene Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q3 2026, its #3709 holding.
SBI Securities first reported a position in enGene Therapeutics in Q4 2024 and has held it in 8 quarters since.
SBI Securities's enGene Therapeutics position peaked at $253 in Q4 2025.
6 funds tracked by Wall St. Rank held enGene Therapeutics as of Q3 2026.

Based on SBI Securities's 13F filing for Q3 2026, filed 22 Oct 2026.